



BRIUMVI (ublituximab-xiiy) ORDER FORM
PATIENT NAME: DOB: WT: HT:
ALLERGIES:
DIAGNOSIS
HAS THE PATIENT PREVIOUSLY RECEIVED: BRIUMVI (ublituximab-xiiy) INO IYES LAST DOSE DATE:
DIAGNOSIS: ICD 10 CODE(S):
MEDICATION ORDERS
DOSE/FREQUENCY: **Orders are valid for 1 year. For a shorter duration, indicate here:
□ 1 <sup>st</sup> : 150 mg IV infusion over 4 hours, at week 0
2 <sup>nd</sup> : 450 mg IV infusion over 1 hour, 2 weeks after the 1 <sup>st</sup> infusion
Subsequent: 450 mg IV infusion over 1 hour, 24 weeks after the 1 <sup>st</sup> infusion, then every 24 weeks
PREMEDICATION: 30 minutes prior to infusion
<ul> <li>□ Methylprednisolone 100 mg IV</li> <li>□ Diphenhydramine 25 mg IV</li> <li>□ Diphenhydramine 25 mg PO</li> <li>□ Diphenhydramine 50 mg IV</li> <li>□ Diphenhydramine 50 mg PO</li> </ul>
☐ Acetaminophen 1000 mg PO ☐ Cetirizine 10 mg PO ☐ Other (dose/route):  STANDARD IV ORDERS
ANCILLARY ORDERS: NURSING ORDERS:
<ul> <li>Infusion Reaction Management per Infusion Solutions</li> <li>If no central IV access, RN to insert peripheral IV.</li> </ul>
Protocol. • Obtain weight before each dose
<ul> <li>Alteplase 2mg IV to declot central IV access per</li> <li>Monitor vital signs (temp, HR, RR, BP) before therapy,</li> </ul>
Infusion Solutions protocol as needed for occlusion. and every 15-30 minutes or with each rate change.
<ul> <li>Flush with 0.9% NaCl and/or Heparin 10 u/ml or 100</li> <li>If an infusion reaction occurs, decrease rate AND</li> </ul>
u/ml per Infusion Solutions protocol. monitor vital signs until symptoms subside. If the
• Lidocaine 1% - up to 0.2 ml intradermally PRN (may reaction persists or worsens, stop the infusion, initiate
buffer with sodium bicarbonate 8.4% in 10:1 ratio). reaction protocol, and notify physician.
Observe patient for 60 minutes after completion of  the group for 15th true influeignes, then for 20 minutes.
therapy for 1 <sup>st</sup> two infusions, then for 30 minutes. <b>LABS</b>
LAB ORDERS: LAB FREQUENCY:
□CBC w/ diff □CMP □CRP □MRI □Every dose
□Serum immunoglobulins □Other: □Other:
REQUIRED DOCUMENTATION
REQUIRED CLINICAL DOCUMENTS: SUPPORTING DOCUMENTS:
<ul> <li>Hepatitis B serology labs or proof of</li> <li>Patient demographic and insurance information.</li> </ul>
immunity/vaccination  • Copy of front and back of insurance card if available.
Serum immunoglobulin (IgG, IgA, IgM) labs     Patient's medication list.
RECOMMENDED CLINICAL DOCUMENTS (provide if available):  • Supporting clinical notes, including past tried and/or
<ul> <li>Baseline labs: CMP, CBC w/ diff failed therapies.</li> <li>Pregnancy test: patient to perform prior to each dose</li> </ul>
<ul> <li>Pregnancy test; patient to perform prior to each dose</li> <li>That all immunizations have been given at least 4 weeks</li> </ul>
prior to initiation of Briumvi for live or live-attenuated
vaccines & at least 2 weeks prior for non-live vaccines.
PROVIDER INFORMATION
PRESCRIBER SIGNATURE (substitution)  PRESCRIBER SIGNATURE (dispense as written)
PRINT NAME (FIRST AND LAST)  DATE